Rx Market Requires “Value,” Not Sales Force Muscle, Merck’s Gilmartin Says
Executive Summary
The commercial success of pharmaceuticals is becoming more closely aligned with the "true value" of a product than with marketing muscle, Merck CEO Ray Gilmartin said during a Lehman Brothers health care conference in Miami March 5
You may also be interested in...
Merck Looks Past Medicare: Next Up, Covering The Uninsured
Merck is preparing for what it believes should be the next big health care policy debate in Washington after Medicare Rx legislation is enacted: health care coverage for the uninsured
Lilly Rallies The Troops: Price Controls Would Trigger “Death Spiral”
Any erosion of free pricing or intellectual property protections in the U.S. pharmaceutical market would lead to a new wave of consolidation in the industry, Lilly CEO Sidney Taurel told the American Enterprise Institute March 18 in Washington, D.C
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011